For the past 18 years, the World Vaccine Congress Washington congress has evolved and grown into the leading vaccines congress globally, with: 300 speakers, 1500 attendees and hundreds of networking opportunities.
The $8.4million project will develop technology to rapidly develop vaccines against known pathogens - such as flu, and unknown pathogens, called Disease X. The project will create a so-called self-amplifying RNA (saRNA) vaccine platform.
The goal was to estimate the minimum cost for achieving vaccine research and development preparedness targets in a portfolio of 11 epidemic infectious diseases, accounting for vaccine pipeline constraints and uncertainty in research and development preparedness outcomes.
University of Texas Medical Branch (UTMB) researchers have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness.
Researchers are developing methods with which viruses for vaccines can be replicated in significantly higher concentrations than before. The researchers produce the pathogens in cell cultures in small bioreactors.
In outbreaks of emerging infectious diseases for which no proven efficacious vaccines exist but investigational vaccines have been developed, it is important both to rapidly test the investigational vaccines and, if effective, to deploy them.
The new system lets scientists quickly assess the full spectrum of antibodies produced in an individual in response to a pathogen or vaccine and determine if these antibodies are likely to be effective against the pathogen.
Advances in certain areas can help scientists understand the immune system and develop innovative vaccines.
A new UK-funded project, the Future Vaccine Manufacturing Hub, is trying a new model that will include a faster process for finding and testing vaccines alongside localized pop-up factories that can get large supplies of vaccines to people within weeks of a threat having been identified.
Vaccine development is a complex process. It involves both public and private partners and requires that a variety of funding issues be considered.